Brief: Kazia Therapeutics Reports Promising Interim Data From Combination Study Of Paxalisib With Radiotherapy In Treatment Of Brain Metastases

Kazia Therapeutics

05/08/2022 17:06

Aug 5 (Reuters) - Kazia Therapeutics Ltd  KZA.AX :
    * KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM
COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF
BRAIN METASTASES
    * KAZIA THERAPEUTICS LTD- INTERIM DATA FROM THE FIRST STAGE
OF
STUDY REPORTS THAT ALL 9 EVALUABLE PATIENTS EXPERIENCED COMPLETE
OR PARTIAL RESPONSE
    * KAZIA THERAPEUTICS LTD-  SAFETY PROFILE OF PAXALISIB IN
COMBINATION WAS BROADLY CONSISTENT WITH MONOTHERAPY EXPERIENCE
IN OTHER CLINICAL TRIALS
    * KAZIA THERAPEUTICS LTD-  RECRUITMENT TO THE EXPANSION
STAGE HAS
ALREADY COMMENCED, WITH THE OBJECTIVE OF RECRUITING AN
ADDITIONAL 12 PATIENTS
    * KAZIA THERAPEUTICS- ENROLMENT TO SECOND STAGE OF STUDY IS
UNDERWAY, ESTIMATE PRELIMINARY DATA FROM SECOND PART OF PHASE I
CLINICAL TRIAL IN CY2023

Further company coverage:  KZA.AX 

 ((Reuters.Briefs@thomsonreuters.com;))